A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

Chen, Ming; Jin, Ying; Bi, Yalan; Yin, Jie; Wang, Yongxue; Pan, Lingya

doi:10.2147/ott.s67812

Cited by 31 publications

(27 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most patients diagnosed with OC, survival is theorized to be 100%, who are still alive after 5-years, are presumably living with the disease rather than living disease-free. 5 Our analysis demonstrated that the DFS was 18.3 months (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). The Surveillance, Epidemiology and End Results-SEER database from 1995 to 2007 with epithelial OC who were actively followed-up and age 20 years or older were included for analyzing OS in the United States (40.692 patients) and OS was 65%, 44%, and 36% at 2, 5, and 10 years, respectively.…”

Section: Discussionmentioning

confidence: 86%

“…Some studies reported that increasing age was most strongly associated with poor survival. 9,10,[18][19][20]22 However, in the other studies of Oge et al 7 and Buldanlı et al 11 revealed that age was not was not effected by the age of the patients in OC.…”

Section: Discussionmentioning

confidence: 91%

“…18 In a study the median DFS and OS for patients with OC were 35.0 months and 54.0 months respectively. 19 In different study done by Anuradha et al in 2014, 1192 Australian women diagnosed with invasive epithelial OC in 2005 were identified through state-based cancer registries and the 5-year OS was 53%. 20 A Swedish study published in 2009 of 682 patients with epithelial OC found a 10-year relative survival rate of 38.4%, the median OS time was 81 months (52-109 months) in OC patients.…”

Section: Discussionmentioning

confidence: 99%

“…6,9,11,17,18,20,23 A multivariate analysis showed that, for OC, the histological grade was a significant prognostic factor for DFS but not for OS. 19 As reported in several studies, grade as important prognostic factors is still controversial.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Pınar¹

2017

UHOD

View full text Add to dashboard Cite

The aim if this study is to explore the impact of the various prognostic factors on overall survival in women with ovarian cancer (OC). Patients diagnosed with gynecologic malignancy in Gynecology Clinic of Baskent University Medicine Faculty between 2010 and 2015 included to study. Patients with ovarian (n= 112) cancers examined retrospectively. Kaplan-Meier, Univariate and Multivariate Cox regression model were performed to estimate for associations of potential variables with survival factors. The mean patient age was 56.4 y, range 20-80. The overall survival was 94.3%, 83.4%, 66.4%, 54.7% and 42.8% at 1, 2 3, 4 and 5 years respectively (60.5 months, range 43-68). 3-year disease-free survival was 25.3% (18.3 months, range 17-20). Multivariate analysis of patients indicated that stage, histology, grade, age at diagnosis, comorbidity, recurrence, BMI, menopausal status and regional distance were independent prognostic factors on survival (p< 0.05). In conclusion, these results will presents a framework to identify fundamental causes in survival for OC.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Pınar¹

2017

UHOD

View full text Add to dashboard Cite

show abstract

“…Currently, OSC is no longer considered to be a homogeneous disease worldwide. It is now recognized as a group of diseases that can be classified based on distinctive morphologic and molecular genetic features [8]. Conventionally, the origin of serous tumour is the ovarian surface epithelium or cortical inclusion cysts.…”

Section: Literature Reviewmentioning

confidence: 99%

Immunohistochemical Expression of Human Epididymis 4 (He4) in Ovarian Serous Carcinoma in Hospital Serdang from the Year 2006- 2013

Rahmat¹,

Ithnin²

2017

Gynecol Obstet

View full text Add to dashboard Cite

Incidence and demography of ovarian cancer: Ovarian cancer is neither a common nor a rare disease. It is the fifth most common cause of cancer death in women worldwide and is the leading cause of death from gynaecological cancer in the western countries [1]. In 2004, about 25,580 women was diagnosed with ovarian cancer (OC) in United States and 16.090 (62%) died from the disease [2]. This owes mainly to presentation with advanced-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage III-IV) due to late symptoms and the lack of effective screening for early disease, as well as increasing chemoresistance along with tumor progression.In Malaysia, ovarian cancer is the fourth leading cause of cancer related deaths and the fifth commonest cause of cancer in women. According to the National Cancer Registry (NCR) 2007, about 658 cases of ovarian cancer diagnosed in 2007 accounted for 6.5% of all female cancer cases (i.e. gynaecological and breast cancers). Out of 426 cases reported, 52% were diagnosed at stage III and IV that is characterized by intraperitoneal spread and distant metastasis. According to the World Health Organization (WHO), ovarian cancer are classified based on histological types, because it is an important surrogate for genetic, prognostic, and, increasingly, predictive information about the response to treatment [3]. This classification categorizes ovarian cancer with regards to their derivation from coelomic surface epithelial cells, germ cells and mesenchyme (the stroma and the sex cord). The malignant epithelial tumor, is the most common group, accounting for 90% of total ovarian cancer. The four most common subtypes of OC are serous, endometrioid, clear cell and mucinous [4]. Among the OC, ovarian serous carcinoma (OSC) is the most common subtypes. General clinical features:Ovarian cancer generally affects women in postmenopausal state with a peak between 55 and 65 years old. At the time of diagnosis, three quarters of patients have locally advanced (FIGO Stage III) or disseminated disease that is characterized by diffuse intraperitoneal spread and/or ascites. FIGO Stage III tumors characteristically metastasize widely within the abdominal cavity, as evidenced by the presence of both solid nodules on the peritoneum and malignant ascites. The symptoms of ovarian carcinoma is non-specific and similar to those seen in other benign condition. This is the possible reason for the delayed seeking of medical attention. The early symptoms include abdominal distension (bloating, increased abdominal size), pelvic and/or abdominal pain, problems with eating (loss of appetite, feeling full quickly), and frequent urination [5]. Based on the study done by Brain, et al. [5], the most well-identified symptoms of ovarian cancer were post-menopausal bleeding (87.4%), and persistent pelvic (79.0%) and abdominal (85.0%) pain. Symptoms associated with eating difficulties and changes in bladder/bowel habits were identified by less than of half the sample. The Human Epididymis 4 (HE4) gene ...

show abstract

Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Cheasley

Nigam

Zethoven

et al. 2020

The Journal of Pathology

View full text Add to dashboard Cite

Low-grade serous ovarian carcinoma (LGSOC) is associated with a poor response to existing chemotherapy, highlighting the need to perform comprehensive genomic analysis and identify new therapeutic vulnerabilities. The data presented here represent the largest genetic study of LGSOCs to date (n = 71), analysing 127 candidate genes derived from whole exome sequencing cohorts to generate mutation and copy-number variation data. Additionally, immunohistochemistry was performed on our LGSOC cohort assessing oestrogen receptor, progesterone receptor, TP53, and CDKN2A status. Targeted sequencing identified 47% of cases with mutations in key RAS/RAF pathway genes (KRAS, BRAF, and NRAS), as well as mutations in putative novel driver genes including USP9X (27%), MACF1 (11%), ARID1A (9%), NF2 (4%), DOT1L (6%), and ASH1L (4%). Immunohistochemistry evaluation revealed frequent oestrogen/progesterone receptor positivity (85%), along with CDKN2A protein loss (10%) and CDKN2A protein overexpression (6%), which were linked to shorter disease outcomes. Indeed, 90% of LGSOC samples harboured at least one potentially actionable alteration, which in 19/71 (27%) cases were predictive of clinical benefit from a standard treatment, either in another cancer's indication or in LGSOC specifically. In addition, we validated ubiquitin-specific protease 9X (USP9X), which is a chromosome X-linked substrate-specific deubiquitinase and tumour suppressor, as a relevant therapeutic target for LGSOC. Our comprehensive genomic study highlighted that there is an addiction to a limited number of unique 'driver' aberrations that could be translated into improved therapeutic paths.

show abstract

A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

Cited by 31 publications

References 35 publications

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Prognostic Factors Affecting Survival in Patients with Ovarian Cancer: A 5-Year Experience in an University Hospital.

Immunohistochemical Expression of Human Epididymis 4 (He4) in Ovarian Serous Carcinoma in Hospital Serdang from the Year 2006- 2013

Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Contact Info

Product

Resources

About